Research programs working toward an HIV cure. Covers reservoir reduction, prevention policy, tumor-like tissue models, and vaccine development.
Researchers challenge assumption that poverty is a risk factor for non-adherence to HIV medication regimens, citing high treatment adherence rates in South African studies. The editorial argues that delivery systems may compromise confidentiality and risk stigmatization if not based on clear evidence.
Researchers found nearly a third of HIV positive male couples became parents through assisted reproduction, while only one out of ten HIV positive female couples were successful. The study's findings suggest HIV positive men may be more suitable candidates for fertility treatments due to lower infection rates.
A new vaccine has shown promise in inducing an HIV-specific immune response in patients with chronic HIV infection, but further research is needed to evaluate its clinical effect. The vaccine, Remune, was found to increase the production of T helper cells that recognize and attack the virus.
The Vanderbilt Meharry Developmental Center for AIDS Research aims to advance treatment and prevention of HIV/AIDS through collaboration and education. The center will focus on racial disparities and minority populations, building on existing collaborations between the two institutions.
A national survey found significant support for HIV vaccine research, with 84% of the public believing efforts to develop a vaccine are 'extremely' or 'very' important. However, there is also concern about misconceptions about vaccine development and testing. The survey highlighted the need for education on ongoing HIV vaccine research.
A study found that HAART reduced the risk of visual impairment and improved quality of life for AIDS patients. Patients who received HAART had a lower incidence of visual acuity loss compared to those who did not, especially those with substantial improvement in their immunity.
A study found that counseling interventions reduced unprotected sex acts among HIV-positive participants by an average of 10 from 14 to 4 per year. However, a group receiving booster sessions showed an unexpected upswing in unprotected sex eight months after intervention, suggesting the need for longer-term follow-up.
The GSK Drug Discovery and Development Research Grant Program provides funding for innovative research into HIV/AIDS treatments. Researchers will be selected based on the potential importance of their project, originality, and ability to conduct the proposed research.
A prototype PDA system made shopping easier and more efficient for participants, who appreciated the ability to identify item locations. However, difficulty holding the device while shopping was a drawback, prompting designers to create an alternative cart-mounted version.
Researchers found that HIV patients develop strong antibody responses against the virus, but these antibodies fail to keep pace with the virus's constant mutation process. This study sheds light on the complex dynamics between the immune system and HIV, highlighting potential avenues for vaccine development.
Reider's innovative method of integrating drug discovery and development led to the rapid approval of life-saving treatments, including indinavir and Singulair. His approach prioritized getting effective drugs to patients faster, despite acknowledging the risks involved.
Researchers discover protein from blue-green algae that inhibits both HIV and Ebola virus infections, potentially leading to new treatments. The protein works by binding to the outside of the viruses and blocking them from entering cells.
The American Academy of Neurology Foundation will honor Jerry Lewis for his decades-long fight against neuromuscular disease. The organization, which supports research and patient care for diseases like muscular dystrophy and ALS, has seen the impact of Lewis's work firsthand.
Similar efficacy responses were seen in both the 908/r regimens and the LPV/r regimen, meeting the primary endpoint of non-inferiority at 24 weeks. Patients achieved positive antiviral responses with both 908/r and LPV/r regimens.
The Phase III, 48-week NEAT study found that 66% of patients taking 908 achieved undetectable viral load compared to 51% on nelfinavir. The study also showed improved safety and efficacy profiles for 908, with lower rates of adverse events and virologic failures.
Researchers found a connection between HIV antiretroviral therapy and impaired triglyceride metabolism, increasing risk of atherosclerosis. Elevated ApoC-III levels were associated with higher triglycerides in both treatment groups.
The study found that boosting GW433908 with ritonavir reduced the incidence of PI-resistance selected by either the study PI or NRTIs ABC and 3TC. In contrast, unboosted 908 had a higher rate of resistance to 3TC and some patients developed mutations associated with APV resistance.
A new AIDS vaccine strategy has been developed by Emory University researchers and is now moving to human clinical trials. The vaccine, which employs two different components, aims to induce the immune system to recognize HIV's distinguishing features, providing a safer alternative for HIV prevention.
A study in rural Uganda found that domestic violence affects nearly half of women, with those whose partners consume alcohol facing a higher risk. The research highlights the connection between domestic violence and HIV risk, suggesting that addressing domestic violence may be crucial to preventing HIV transmission.
China's blood banking system is fragmenting due to rural-urban differences and has a scarcity of volunteer donors, leading to paid donations and illegal activities. Improvements are needed to adopt a volunteer-donor-only system, increasing education and training for those involved in blood collection and transfusion.
Researchers at UIC provided the first images of HIV in living cells, revealing how the virus enlists host assistance to wreak havoc on the body's defenses. The visualization, which took four years to develop, shows HIV particles hitching a ride aboard dynein, a molecular motor, and crossing the microtubular highway to reach the nucleus.
The Global Health Research Initiative Program for New Foreign Investigators (GRIP) provides support to young researchers from developing countries. The program aims to enhance scientific research capacity and address critical global health issues, including AIDS, cancer, and neurological disorders.
Researchers discovered that an individual could become infected with two closely related strains of HIV, highlighting the challenges in creating a vaccine against this highly variable virus. The study found that a hypothetical vaccine against one strain may not protect against other closely related strains.
The Emory Center for AIDS Research (CFAR) has received a five-year grant from the National Institutes of Health to further HIV/AIDS research and prevention efforts. With $33.5 million in NIH funding, the CFAR will build on recent advances in immunology, vaccines, and drug development.
In the 48-week SOLO trial, patients taking GW433908/r QD achieved undetectable viral load in 68%, compared to 65% of those taking nelfinavir BID. The study also showed improved efficacy in patients with high or low CD4 counts at baseline.
A new DNA vaccine has entered human trials, incorporating parts of four HIV genes to target various subtypes. The trial aims to determine the vaccine's safety and immune response, with expanded tests planned for international sites.
A recent study published in Psychosomatics found that HIV-positive patients who perceive their illness as a 'punishment' experience lower self-esteem and increased depression. The research highlights the need for addressing psychosocial issues, such as punishment beliefs about HIV, on self-care and medical outcomes.
Research in Kenya found that pregnant women with both HIV and malaria are at higher risk of developing anaemia, while their children also face a greater risk. However, the transmission of HIV from mother to child is less frequent when the mother has a mild malaria infection.
The new CIPRA grant will address HIV/AIDS as a family issue, not just an individual problem. The research aims to develop practical techniques tailored to the needs of South African families, with a focus on prevention, treatment, and social support services for those living with HIV/AIDS.
UCSF's Institute for Global Health has been awarded $4.5 million by the CDC to assist in global AIDS programs, focusing on training, technical assistance, and research in resource-constrained countries. The consortium will also establish regional coordinating centers in Brazil, India, and Zimbabwe.
Amanda Fisher has been awarded the prestigious EMBO Gold Medal for her exceptional work in European molecular biology. The award recognizes her achievements as a role model for scientists in Europe.
Researchers found that long-term nonprogressors' cells were better able to divide and produce perforin, a molecule that helps kill off infected cells. This discovery is crucial for developing effective vaccines and therapeutic treatments that improve CD8+ T cell function.
Researchers Irwin Chaiken, Nouri Neamati, Alan C. Sartorelli, Nan-Sook Lee, Elias Lolis, and Min Lu received awards for their work on preventing HIV from infecting host cells, developing integrase inhibitors, and making current drugs more effective. The $500,000 award aims to encourage new approaches in HIV/AIDS therapy research.
The European Molecular Biology Laboratory highlights the potential for genomic research to combat tropical diseases. However, commercial interest in developing treatments has been limited, and it will be necessary to combine efforts from not-for-profit organizations and private funds to support research in developing countries.
A new detection method uses gold nanoparticles and DNA probes to quickly identify multiple diseases, surpassing conventional methods in sensitivity, selectivity, and speed. This technique has the potential to be inexpensive and widely available.
The NIH has launched a new research program to better understand the role of stigma in global health and develop evidence-based interventions to mitigate its negative effects. The program aims to break new ground by providing information to help minimize stigma's impact on health.
The Bill & Melinda Gates Foundation is funding a study at UCSF to test diaphragms as an HIV prevention method. The diaphragm holds promise for preventing HIV transmission, particularly in women, who are disproportionately affected by the disease.
Scientists have gained valuable insights into AIDS by studying the simian immunodeficiency virus in monkeys. Researchers are now exploring ways to vaccinate against HIV transmission and eliminate latent viruses.
A new HIV vaccine candidate has shown promising results, targeting a shared characteristic of all HIV strains and generating antibodies that neutralize a wide range of isolates. The complex could serve as a useful model for HIV vaccine development, bringing researchers closer to their goal of developing an effective vaccine.
A recent study published in the New England Journal of Medicine found that the transmission rate of drug-resistant HIV had more than doubled among patients in North America. The study, which analyzed over 300 patients, revealed a significant increase in the prevalence of viral mutations associated with resistance.
A study of 12,804 SAH cases found that mortality rates decreased with increasing hospital volume, with highest-volume hospitals having 32% lower mortality. Longer stays and higher costs were also associated with higher-volume hospitals.
NIAID-funded studies explore dual protease inhibitors, herpes simplex virus 2 risk factor for HIV infection in India, and anti-HIV antibodies' influence on HIV evolution. The conference also features the world's largest preventive HIV vaccine trial.
A study in Zimbabwe found that women are willing to use diaphragms as a potential HIV prevention method. Diaphragms may increase the effectiveness of new microbicides designed to prevent HIV acquisition, according to principal investigator Nancy Padian.
Researchers at the University of Pittsburgh discovered that even mild elevations in liver enzymes ALT and AST are associated with a nearly twice higher death rate compared to normal levels. Elevated enzymes signal liver injury and can result from HIV treatment, viral hepatitis, or alcohol abuse.
Northwestern researcher Robert L. Murphy calls for simplified, less toxic HIV therapies due to complex regimens and adverse effects. He discusses potential new treatments like atazanavir, a single-daily-dose protease inhibitor with minimal side effects.
A five-year, $14.8 million NIH-funded award will support HIV/AIDS research in China, focusing on epidemiologic and behavioral interventions, pathogenesis of the virus, safety and efficacy of anti-HIV drugs, and vaccine development. The award aims to improve HIV/AIDS treatment and prevention measures in resource-limited countries.
Researchers at Ohio State University found that methamphetamine exposure can dramatically increase the replication of lentiviruses like FIV and HIV in astrocyte cells, a type of nerve cell. This could lead to new insights into how these viruses spread in the brain and may impact dementia treatment.
UCSF researchers argue that funding HIV prevention interventions in sub-Saharan Africa is 28 times more cost-effective than treating individuals with highly active antiretroviral therapy (HAART). Implementing six proven prevention interventions can save a maximum number of lives with limited funds available, according to the study.
The HVDDT program aims to bring a safe and effective HIV vaccine closer to reality by partnering academic research centers with private industry. Early tests in monkeys showed promising results, with vaccinated animals developing strong immune responses that protected against disease.
Researchers are making progress in developing preventive HIV vaccines, with six potential candidates tested in clinical trials over the past five years. The National Institute of Allergy and Infectious Diseases is currently sponsoring multiple clinical trials, which will require tens of thousands of additional volunteers.
A new method to prevent HIV from infecting healthy cells has been discovered by a team of researchers at the University of Illinois. The study found that reverse-chirality D-peptides can block the virus's entry into cells, providing a potential new therapeutic option.
The GlaxoSmithKline Drug Discovery and Development Award provides funding for innovative HIV/AIDS research, including therapies aimed at treating infection and preventing transmission. The award is intended to further the development of inventive treatments for HIV/AIDS.
Researchers at Rush University Medical Center are conducting a Phase I clinical trial to test the safety and efficacy of an HIV vaccine in healthy individuals. The vaccine has shown promise in eliciting specific antiviral cellular immune responses and is generally well-tolerated.
Researchers found that measles triggers intense immune system activation, temporarily suppressing HIV levels in children. The study suggests a potential clue to understanding HIV pathogenesis and immunity.
A second-stage HIV vaccine trial has started in London and Oxford, recruiting 120 volunteers to assess the vaccine's safety and dosage. The trial aims to establish optimum vaccination schedules and booster injections to prevent HIV infection.
Researchers found that two American infants were infected with African strains of HIV as early as 1994. The study suggests that more complicated regimens work best to combat the spread of HIV in pediatric patients, but may pose social problems for children entering adolescence.
A study shows that black teen girls who rarely talked to their parents about sex and STD prevention were less likely to report condom use. Parents can help motivate their daughters to discuss safe sex techniques with partners, according to researchers.
The Pediatric AIDS Clinical Trials Group will support clinical trials sites, a statistical center, and operations center with renewed funding. The new agenda emphasizes five key areas: perinatal transmission, pediatric treatment, adolescent treatment, long-term evaluation of antiretroviral therapies, and domestic and international coll...
Researchers found that HIV protein Vpr halts infected T cells from dividing, allowing the virus to replicate efficiently. The study uses a new laboratory technique to detect infected cells, providing a potential window into patient outcomes and treatment options.
A recent decision by NIAID has halted a proposed Phase III HIV vaccine efficacy trial, citing concerns about the level of CD8 cellular immune response. However, a new trial will proceed with a similar vaccine combination, ALVAC-HIV and AIDSVAX, to assess its efficacy in Thailand.